Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II Trial of Sequential Epirubicin/Vinorelbine in Patients With Advanced Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00176488
• Other study ID #: CDR0000539565
• Secondary ID: P30CA072720CINJ
• Status: Terminated
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: September 18, 2013
• Start date: June 2003
• Est. completion date: October 2009

Study information

• Verified date: September 2013
• Source: Rutgers, The State University of New Jersey
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving epirubicin together with vinorelbine may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving epirubicin together with vinorelbine works in treating patients with stage II, stage III, or stage IV breast cancer.

Description:

OBJECTIVES:

• Assess the efficacy of sequential use of epirubicin hydrochloride followed by vinorelbine ditartrate in patients with stage IIB, IIIA, IIIB, or IV breast cancer.

• Measure the biological response to this regimen in sequential tumor biopsies and peripheral mononuclear cells from these patients.

• Correlate tumor response with changes in the gene expression of microtubule-associated protein 4.

OUTLINE: Patients receive epirubicin hydrochloride IV on day 1 and vinorelbine ditartrate IV over 6-10 minutes on days 3 and 17. Patients also receive filgrastim (G-CSF) subcutaneously on days 4-14 or pegfilgrastim IV on day 4.

For patients with stage IIB (T3, N0), IIIA, or IIIB disease, treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. For patients with stage IV disease, treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline and after course 1 for research studies. Patients with accessible tumor for biopsy undergo sequential biopsies and core needle biopsies at baseline and after course 1. Tumor tissue samples are used for determination of p53 status by western blot analysis, immunohistochemistry, and DNA sequencing. Microtubule-associated protein 4, p53, and p21/WAF1 expression is analyzed by western blotting.

After completion of study treatment, patients are followed for 1 month.

PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed stage IIB (T3, N0), IIIA, IIIB, or IV breast carcinoma

• Original tumor must be available for analysis of p53 status

• Measurable disease, defined as any lesion that can be accurately measured in = 1 dimension with longest diameter = 20 mm using conventional techniques OR = 10 mm with spiral CT scan

• Stage IIIB disease will be assessed by clinical exam (monitoring skin changes as well as tumor size)

• No visceral crisis (lymphangitic pulmonary spread, or liver or marrow replacement sufficient to cause significant organ dysfunction)

• No untreated CNS metastases

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• ECOG performance status 0-2

• Life expectancy = 8 weeks

• Absolute neutrophil count = 1,000/mm³

• Platelet count = 100,000/mm³

• Hemoglobin = 10 g/dL

• Bilirubin normal

• AST = 3 times normal (= 5 times normal if liver metastases are present)

• Creatinine = 1.5 mg/dL

• Ejection fraction = lower limit of normal by MUGA scan or ECG

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective nonhormonal contraception

• No other malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

• No pre-existing disease (i.e., cardiac, pulmonary, neurologic, or other disease) that the investigator judges to be clinically significant

• No active infectious process, severe malnutrition, or intractable emesis

PRIOR CONCURRENT THERAPY:

• Recovered from all prior therapy

• At least 3 weeks since prior radiotherapy

• At least 3 weeks since prior chemotherapy

• Maximum prior doxorubicin hydrochloride dose must be = 300 mg/m² OR equivalent anthracycline (epirubicin hydrochloride) dose must be = 540 mg/m² OR calculated total anthracycline dose must be = 540 mg/m² (determined as 1.8 times total doxorubicin hydrochloride dose plus epirubicin hydrochloride dose)

• No prior chemotherapy for metastatic disease

• Prior adjuvant chemotherapy, radiotherapy, and/or hormonal therapy for breast cancer allowed

• No concurrent radiotherapy except for brain metastases

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• epirubicin
Epirubicin (100 mg/m2) will be given on Day 1
• vinorelbine
Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.

Locations

Country	Name	City	State
United States	Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School	New Brunswick	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
University of Medicine and Dentistry of New Jersey	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the Sequential Use of a DNA Damaging Drug (Epirubicin) Followed by a Vinca Alkaloid (Vinorelbine) in the Treatment of Breast Cancer.		10 years	No
Secondary	Biological Response to Epirubicin and Vinorelbine Administered in Patients With Breast Cancer in Sequential Tumor Biopsies and Peripheral Blood Mononuclear Cells.		10 years	No
Secondary	Correlate Tumor Response With Changes in the Gene Expression of Microtubule Associated Protein 4 (MAP4).		10 years	No